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Background: Low adherence to bisphosphonate therapy is associated with increased fracture risk. Factors
associated with discontinuation of osteoporosis medications have not been studied in-depth. This study assessed
medication discontinuation and switching patterns among Medicare beneficiaries who were new users of
bisphosphonates and evaluated factors possibly associated with discontinuation.
Methods: We identified patients initiating bisphosphonate treatment using a 5% random sample of Medicare
beneficiaries with at least 24 months of traditional fee-for-service and part D drug coverage from 2006 through
2009. We classified medication status at the end of follow-up as: continued original bisphosphonate, discontinued
without switching or restarting, restarted the same drug after a treatment gap (≥ 90 days), or switched to another
anti-osteoporosis medication. We conducted logistic regression analyses to identify baseline characteristics
associated with discontinuation and a case-crossover analysis to identify factors that precipitate discontinuation.
Results: Of 21,452 new users followed respectively for 12 months, 44% continued their original therapy, 36%
discontinued without switching or restarting, 8% restarted the same drug after a gap greater than 90 days, and
11% switched to another anti-osteoporosis medication. Factors assessed during the 12-month period before
initiation were weakly associated with discontinuation. Several Factors measured during follow-up were associated
with discontinuation, including more physician visits, hospitalization, having a dual-energy X-ray absorptiometry test,
higher Charlson comorbidity index scores, higher out-of-pocket drug payments, and upper gastrointestinal
problems. Patterns were similar for 4,738 new users followed for 30 months.
Conclusions: Among new bisphosphonates users, switching within and across drug classes and extended
treatment gaps are common. Robust definitions and time-varying considerations should be considered to
characterize medication discontinuation more accurately.
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Adherence to oral bisphosphonate therapy has been re-
ported to be suboptimal, with about 50% of patients who
initiate treatment stopping within one year [1-3]. This
poor adherence is thought to increase the risk of conse-
quent morbidity (e.g., fractures) and associated costs [4].* Correspondence: yunn@uab.edu
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reproduction in any medium, provided the orAdherence to osteoporosis medications has been evalu-
ated in many studies in the United States (US) [5-10],
and certain factors inversely related to adherence have
been identified, including drug related side effects, hav-
ing multiple comorbid conditions, inconvenient dosing,
higher cost, and hospitalization during the one year
period before the initiation of osteoporosis medications.
However, our understanding of factors related to poor
adherence may be incomplete due to methods used to
define discontinuation. Once patients discontinue their
specific osteoporosis medication, some will switch to. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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vious research did not address patients’ switching agents,
either to a different agent within the same therapeutic
class, or to an agent in a different therapeutic class. One
of the few analyses addressing osteoporosis medication
discontinuation reported that 30% of patients resumed
their medication within six months of discontinuation,
and 48% resumed their medication within one year [4].
Hence, the commonly used methods of measuring ad-
herence, which classify patients as discontinued after a
gap of at least 90 days even if they later restart the same
therapy [11,12], or exclude patients if they switch to an-
other anti-osteoporosis medication or different dosage
[13,14], may underestimate overall treatment adherence
and hinder understanding of the utilization of bisphos-
phonate therapy. For a study of the efficacy, effectiveness,
and/or safety of a specific type, route, or dose of bisphos-
phonate (e.g., alendronate, risedronate, ibandronate), a
narrow definition of discontinuation may be appropriate.
However, research on factors associated more generally
with adherence, adverse effects or effectiveness of being
treated with any anti-osteoporosis medication may benefit
from a broader definition. In addition, factors precipitating
the discontinuation of anti-osteoporosis medications have
not been studied in-depth. In the osteoporosis field, these
issues are of key importance given the growing interest
in a ‘drug holiday’ [15,16] during which time patients
are instructed to cease bisphosphonate therapy for a time
(e.g., 1–3 years), making additional work on methods for
discontinuation of anti-osteoporosis drugs important and
timely. Accordingly, we conducted a study to describe dis-
continuation and switching patterns of anti-osteoporosis
medications in the national US Medicare population, to
evaluate factors associated with discontinuation using a
variety of definitions, and to identify factors precipitating
discontinuation of all anti-osteoporosis therapy.
Methods
Overview of design and data sources
To assess anti-osteoporosis medication utilization pat-
terns and to identify baseline factors associated with al-
ternative definitions of discontinuation, we conducted a
retrospective cohort study. To identify factors precipitat-
ing discontinuation among adherent patients, we con-
ducted a case-crossover analysis, nested within the cohort
study [17]. Both the cohort and the case-crossover ana-
lyses used 2006–2009 data on a national 5% random sam-
ple of Medicare beneficiaries, obtained from the Centers
for Medicare and Medicaid Services (CMS) Chronic
Condition Data Warehouse [18]. For each beneficiary,
data included information on demographic and insur-
ance coverage; claims for inpatient, outpatient, skilled
nursing facility, noninstitutional provider, home health,
hospice, durable medical equipment services; and claimsfor prescription drugs. The institutional review board of
the University of Alabama at Birmingham approved the
study.
Cohort study design
Eligible subjects for the cohort study were Medicare
beneficiaries who were 65 years of age or older; lived in
the US; were enrolled continuously in traditional Medi-
care fee-for-service and pharmacy coverage (Parts A, B
and D) and not in a Medicare Advantage plan for at
least 13 continuous months (12 months baseline and at
least one month follow-up time); and were newly treated
with a bisphosphonates. Bisphosphonate medications
included infusion (IV) zoledronic acid, IV ibandronate,
oral ibandronate, oral alendronate, or oral risedronate,
during the period 2007 to 2009. We defined new treat-
ment with a particular bisphosphonate as therapy initiated
after a baseline period of 12 months during which no bis-
phosphonate prescription was filled and no administration
of IV bisphosphonate occurred. We defined the “original”
bisphosphonate as the one taken at initiation. We ex-
cluded patients who filled a prescription for raloxifene,
calcitonin or teriparatide during baseline and for each
beneficiary, follow-up began on the earliest treatment ini-
tiation date during the study period and ended on the
earliest of first date of losing full Medicare coverage, the
death date, or 12/31/2009.
We examined utilization patterns during a follow-up
period of 12 months, during which full Medicare coverage
was required. We classified patients’ medication status at
the end of 12 months of follow-up into four mutually ex-
clusive groups: 1) continued original bisphosphonate use
without a treatment gap, 2) discontinued without switch-
ing to a different osteoporosis medication or restarting the
original bisphosphonate, 3) restarted the same bisphos-
phonate after a treatment gap or 4) switched to another
drug (a different bisphosphonate, raloxifene, calcitonin or
teriparatide). We defined a treatment gap as a period of at
least 90 days, occurring after the end of the days supplied
by a prescription or administration of a particular bisphos-
phonate drug and during which there was no further pre-
scription fill or administration of the drug. We assigned
days supplied as 90 days for IV ibandronate (administered
at three-month intervals) and 365 days for IV zolendronic
acid (administered annually). Based on the medication
status at the end of 12 months of follow-up, we de-
fined discontinuation using two definitions in the analysis
evaluating the association between baseline characteristics
and discontinuation of bisphosphonate therapy (Figure 1).
Definition I classified a beneficiary as discontinued only if
s/he had discontinued all anti-osteoporosis drugs as of the
end of follow up. Definition II classified a beneficiary as
discontinued if s/he had discontinued all anti-osteoporosis
drugs as of the end of follow up, or switched to another
Figure 1 Anti-osteoporotic medication discontinuation and switching among new bisphosphonate users at the end of 12 months of
follow up. Discontinuation definition I: Totally discontinued all anti-osteoporosis drugs as of the end of follow up. The total percentage of
discontinuation I at the 12 months of follow-up is 38%. Discontinuation definition II: Totally discontinued all anti-osteoporosis drugs as of
the end of follow up, or switched to another anti-osteoporosis medication, or stopped then restarted the same anti-osteoporosis drugs.
The total percentage of discontinuation II at the 12 months of follow-up is 52%. As permitted N (CMS does not allow reporting of N < 11).
Alendronate, risedronate, ibandronate, zoledronic acid, calcitonin, raloxifene, teriparatide were considered as different anti-osteoporosis
medications. Branded and generic alendronates were considered as the same medication.
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anti-osteoporosis medication, or restarted the same anti-
osteoporosis drug after a treatment gap of ≥ 90 days.
Calcitonin, raloxifene, teriparatide were considered as
different anti-osteoporotic medications during follow-up.
For example, if a patient restarted the same bisphospho-
nate after a treatment gap, and then switched to calcitonin
until the end of follow-up, we classified the patient as not
discontinued in definition I, but discontinued in definition
II. To assess longer-term adherence and switching, we
conducted similar analyses among patients who had at
least 30 months of follow-up, classifying their medication
status at the end of 30 months of follow-up using the
same definitions of discontinuation (Additional file 1).
Case-crossover study design
The case-crossover design enables studying the associ-
ation between transient exposure, and an acute event by
comparing exposure in a period shortly before the event
with the patient’s usual frequency of that exposure [19].
Because control information for each subject is based on
his or her own past exposure experience in this design,
results are not confounded by risk factors that are stable
over time [19-21].
To identify and quantify factors that may precipitate
discontinuation to anti-osteoporosis medication, we
evaluated each cohort member’s adherence to bispho-
sphonates during the first 12 months of treatment using
the medication possession ratio (MPR), calculated as the
total days of bisphosphonate exposure during the first12 months of follow-up divided by 365 days, and then
classified a subject as adherent to bisphosphonate therapy
if s/he had an MPR ≥ 80%. The case-crossover analysis
included subjects from the cohort study who were ad-
herent to their original bisphosphonate during the first
12 months after treatment initiation, without switching,
stopping and/or restarting their original bisphosphonate
at any time during the first 12 months follow-up, who
then discontinued their original bisphosphonate therapy
(i.e., experienced a gap of 90 days or longer) during the
subsequent follow-up (i.e., > 12 months after treatment
initiation). We excluded those who had a hospitalization
or skilled nursing home stay in the first 90 days after dis-
continuation in order to minimize misclassification, be-
cause claims data may not accurately measure drugs used
during inpatient and skilled nursing facility stays (21). The
follow-up period for identifying discontinuation began
12 months after initiation and continued until the earliest
of the loss of full Medicare coverage, discontinuation,
death, or 12/31/2009. For each eligible subject, we defined
the “case” (or “hazard”) period as the 30 days immediately
before bisphosphonate discontinuation, and we specified
five “control” periods as the five 30-day periods immedi-
ately before the hazard period (Figure 2) [17,21,22].
Factors possibly related to discontinuation
Factors measured during the baseline period for the co-
hort study and analyzed for possible association with differ-
ent definitions of discontinuation included demographics,
history of co-morbid conditions, history of preventive
Figure 2 The case-crossover design of identifying factors precipitating discontinuation of osteoporosis medications.
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a low income subsidy and use of prescription drugs other
than anti-osteoporosis medications. Demographic charac-
teristics included age, gender, race, geographic region and
residential area-level income, all assessed as of the start
of follow-up. We estimated income, as a proxy for so-
cioeconomic status, using beneficiaries’ nine-digit ZIP
codes linked to their 2000 Census block group of resi-
dence and the corresponding median household income
[23]. We identified osteoporosis and history of fractures
using International Classification of Disease (ICD)-
9th revision diagnosis codes specific to the particular
fracture sites from inpatient and physician encounter
claims. ICD9 codes for osteoporosis included 733.0,
733.00, 733.01, 733.02, 733.03, 733.09, and for frac-
ture included 800.xx-829.xx, and 733.1x. Other med-
ical conditions, which may associated with fracture
and consequently with anti-osteoporosis therapy pat-
terns, included glucocorticoid-related and fall-related
(predisposing to falls) conditions, diabetes, chronic kidney
disease, depressive illness, acute myocardial infarction,
other heart disease, metabolic bone disease and can-
cer [23]. We identified these conditions using the criter-
ion of at least one diagnosis from inpatient or physician
evaluation/management claims during baseline. Medica-
tions possibly associated with medication discontinuation
or risk of fractures included anticonvulsants, antide-
pressants, antipsychotics, antihypertensives, lipid-lowering
drugs, non-steroidal anti-inflammatory drugs, steroids,
proton pump inhibitors, H2-receptor blockers, hormone
replacement therapy, thiazolidinediones, and aromatase
inhibitors. We identified these medications using the cri-
terion of at least one claim for a prescription filled in
Medicare Part D data during baseline.
Factors considered as possibly precipitating medication
discontinuation in the case-crossover analysis (see
detailed algorithm codes in Additional file 2) included(DXA) testing, skilled nursing home stays, hospitalization
for any cause, entering the part D coverage gap [24], hav-
ing a rheumatologist or endocrinologist visit, having
an oncologist visit, eligibility for a low income sub-
sidy, the occurrence of fracture, malignancy, upper
gastrointestinal disease, adverse events (including osteo-
necrosis of the jaw, atrial fibrillation, esophageal cancer,
renal disease, subtrochanteric or femoral shaft fractures),
total number of physician visits, number of different medi-
cations, the Charlson comorbidity index [25], total Medi-
care costs and out-of-pocket drug costs. The first eight
factors were dichotomous, whereas the rest had multiple
categories based on their distribution during the last
30 days of the first 12 months of treatment.
For analyses evaluating the effect of baseline factors
on discontinuation, the outcomes were the two alter-
native definitions of discontinuation at the end of 12 months
following bisphosphonate initiation. For the analysis
of factors precipitating discontinuation of anti-osteoporosis
therapy, we selected as cases only those who totally
discontinued bisphosphonate use at the end of follow-
up.
Analysis
We evaluated new bisphosphonate treatment patterns
during 2007–2009 graphically for each bisphosphonate
including branded alendronate without vitamin D,
branded alendronate with vitamin D, generic alendro-
nate, risedronate, oral ibandronate, IV ibandronate and
IV zoledronic acid. We identified the number of new
users of each specific bisphosphonate drug, calculated
the proportion of each drug among all new users of
bisphosphonates for each quarter of the study period,
and calculated the proportion by medication status as of
the end of 12 months of follow-up period.
We compared the baseline characteristics by medica-
tion status of new bisphosphonate users at the end of
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ference scores to evaluate the magnitude of differences
between groups. We considered standardized difference
scores that were less than 0.1 as clinically unimportant
[26]. We conducted logistic regression analyses to identify
baseline characteristics associated with the two different
definitions of discontinuation at the end of 12 months
of follow-up. Finally, we repeated all analyses to iden-
tify baseline characteristics associated with the two differ-
ent definitions of discontinuation for patients who had
at least 30 months of follow-up at the end of 30 months.
These analyses used the odds ratio (OR) with its 95%
confidence interval (CI) as the measure of association.
Statistical significance was assessed at the alpha level
of 0.05.
In the case-crossover analysis, we compared exposures
in a subject’s hazard period (30 days immediately before
discontinuation) and control periods (five 30-day periods
immediately before the hazard period) [17,21,22]. In sen-
sitivity analyses, we compared exposures in the 30 days
immediately before discontinuation and four, three, two
and one 30-day periods immediately before the hazard
period respectively. We also carried out an additional
sensitivity analysis in which the hazard and control time
windows were extended to 60 days: that is, this analysis
included one hazard period, consisting of the 60 days
immediately before discontinuation, and two 60-day
control periods immediately before the hazard period,
so that the study period is as long as the main ana-
lysis We used conditional logistic regression models
to compute ORs for the association between factors
of interest and discontinuation for the case-crossoverFigure 3 Proportion of Medicare beneficiaries starting specific type
quarter, 2007–2009.analysis. All statistical analyses were performed in SAS 9.3
(SAS institute).
Results
We identified 30,990 Medicare beneficiaries in the 5%
sample who initiated a bisphosphonate during 2007–
2009 (Figure 3). The number of patients initiating each
agent was 11,421 for generic alendronate, 6,173 for rise-
dronate, 4,394 for oral ibandronate, 5,251 for branded
alendronate without vitamin D, 1,794 for IV zoledronic
acid, 1,532 for branded alendronate with vitamin D, and
425 for IV ibandronate. Overall, branded alendronate
without vitamin D was the most commonly prescribed
medication in 2007, whereas generic alendronate was
the most commonly used drug in 2009.
Of the 30,990 new users of bisphosphonates identified
in 2007–2009, 21,452 were eligible for inclusion in ana-
lyses of medication status at the end of 12 months of
follow-up. (i.e., they had at least 12 months of coverage
after the earliest treatment initiation date) (Figure 1). Of
these new users followed for 12 months, 44% continued
the same therapy, 36% totally discontinued without switch-
ing or restarting after a treatment gap, 8% restarted
the same drug after a gap of greater than 90 days after
the end of the days’ supply, and 11% switched to another
bisphosphonate or non- bisphosphonate drug. By the
end of 12 months of follow-up, most of beneficiaries
who restarted the same drug after a treatment gap con-
tinued taking the anti-osteoporosis medications until
the end of follow-up, whereas 17% of beneficiaries who
switched to another drug discontinued all anti-osteoporosis
medications. Of 4,738 eligible new users followed fors of bisphosphonates among all new users, by calendar
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tally discontinued, 12% restarted the same drug after
a gap, and 24% switched to another osteoporosis drug
without a gap. By the end of 30 months of follow-up,
30% beneficiaries who switched to another drug discontin-
ued all anti-osteoporosis medications (Additional file 1).
The standardized difference scores indicated that base-
line characteristics of these four groups were statistically
comparable except for history of hospitalization, resi-
dency in long-term care and history of DXA (Table 1).
Compared to beneficiaries who discontinued without
switching or restarting at the end of 12 months follow-
up, beneficiaries who continued the original bispho-
sphonates were more likely to have undergone DXA
testing and to have been residing in long-term care;
beneficiaries who switched to another drug were more
likely to have had a DXA and hospitalization during
baseline.
With 12 months of follow-up, factors associated with
an increased ORs for total discontinuation of bisphos-
phonate therapy (definition I) included being male, being
Hispanic versus non-Hispanic White, living in the South,
having a Charlson score greater than zero, and having
more than 10 physician visits during the baseline year
(Table 2). Factors associated with a lower odds of total
discontinuation included area income over $30,000, hav-
ing a long-term care facility stay during baseline, having
a DXA test during baseline, having rheumatologist or
endocrinologist visit during baseline, having an oncolo-
gist visit during baseline, having history of osteoporosis
and taking proton pump inhibitors during baseline All
of these associations were weak, with positive associa-
tions having ORs below 1.5 and inverse associations hav-
ing ORs of 0.8 or 0.9. Results were similar in the analysis
that used discontinuation definition II after 12 months
of follow-up and in analyses of both definitions of dis-
continuation after 30 months of follow-up (Additional
file 3). The range of the c-statistics of the logistic regres-
sion models for these analyses was 0.58-0.61.
Among subjects in the cohort study with high ad-
herence (MPR ≥ 80%) in their first 12 months follow-
ing bisphosphonate initiation, 922 patients subsequently
discontinued their bisphosphonate therapy (Table 3). Fac-
tors, measured in the 30 days immediately preceding dis-
continuation, associated with discontinuation were having
a DXA test, hospitalization, upper gastrointestinal symp-
toms or conditions, having more than four physician
visits, Charlson score greater than 2, total out-of-pocket
drug payments ≥ $20. Taking ≥ 3 different medications was
inversely associated with discontinuation. The results of
the sensitivity analyses were qualitatively similar to those
of the main analysis, regardless of the number of control
periods or the duration of the hazard and control periods
(30 days v. 60 days) (data not shown).Discussion
We found large temporal changes in the pattern of use
of several types of bisphosphonates in 2007–2009 among
Medicare beneficiaries. Our analysis of factors associated
with different definitions of discontinuation found fac-
tors measured at baseline were, at most, weakly associ-
ated with discontinuation and differed little according to
the definitions of discontinuation. However, in the case-
crossover analysis evaluating the effect of factors measured
immediately before discontinuation, a DXA test, having
upper gastrointestinal problems, having more physician
visits, higher Charlson comorbidity scores, and higher
out-of-pocket drug payments, were associated with total
discontinuation of bisphosphonate therapy after one year
of high adherence, whereas a higher total number of all
types medications dispensed was associated inversely with
discontinuation.
Starting in 2008, we found the major increases in bis-
phosphonate utilization were for generic alendronate
and IV zoledronic acid, and the major decreases were
for branded alendronate products and risedronate. Our
findings are consistent with a report from Medco Health
Solutions, Inc (a healthcare company) indicating that
branded alendronate lost 84% of its market share from re-
tail stores and 94% of its market share from mail pharma-
cies during the first 30 days after the launch of generic
products [27]. Several factors could explain the increase in
IV/injection bisphosphonates utilization that we observed
during the 2007–2009 time period. More aggressive mar-
keting and perceptions of potentially better adherence
with IV compared to oral bisphosphonates could lead to
greater prescribing of IV therapies. Parenteral admin-
istration also may minimize certain side effects, such as
gastrointestinal upset, and avoids the complex instructions
required for proper administration of oral bisphospho-
nates [28].
We also found that switching within the bisphospho-
nates class, switching out of the bisphosphonate treat-
ment class, and having treatment gaps were common
among new bisphosphonate users. For our purposes, dis-
continuation was defined in two alternative ways: first,
as total discontinuation of any osteoporosis medications;
second, as total discontinuation, having a therapy gap then
restarting the same bisphosphonate, or switching to an-
other therapy during follow-up. Compared to the strict
definition (I) of discontinuation, an additional 17-29% of
people were classified as discontinued due to switching to
other types of bisphosphonate or to non-bisphosphonate
osteoporosis medications or due to a gap in therapy with a
particular type of bisphosphonate.
Our findings are consistent with those of prior studies
showing that people are prone to switch or restart bispho-
sphonates after discontinuation [4,29]. Using 1996–2002
Pharmaceutical Assistance Contract for the Elderly (PACE)
Table 1 Baseline demographic and comorbidity characteristics by medication status of new bisphosphonate users at
the end of 12 months follow up











N 9,510 7,827 1,819 2,296
Age, years (SD) 78 (6.8) 78 (6.8) 78 (6.7) 78 (6.8)
Median Household Income, $ (SD) 46,318 (22,808) 44,415 (22,715) 45,015 (23,123) 45,142 (22,540)
Sex
Female 8,562 (90.3) 6,965 (89.0) 1,639 (90.1) 2,104 (91.6)
Male 948 (10.0) 862 (11.0) 180 (9.9) 192 (8.4)
Race/ethnicity
Black 455 (4.8) 455 (5.8) 125 (6.9) 94 (4.1)
White 8,194 (86.2) 6,486 (82.9) 1,456 (80.0)* 1,920 (83.6)
Asian 360 (3.8) 319 (4.1) 92 (5.1) 130 (5.7)
Hispanic 285 (3.0) 382 (4.9) 95 (5.2) 107 (4.7)
Other 216 (2.3) 185 (2.4) 51 (2.8) 45 (2.0)
Geographic region
Northeast 1,717 (18.1) 1,340 (17.1) 355 (19.5) 382 (16.6)
Midwest 2,534 (26.6) 1,805 (23.1) 417 (22.9) 568 (24.7)
South 3,540 (37.2) 3,287 (42.0) 701 (38.5) 903 (39.3)
West 1,719 (18.1) 1,395 (17.8) 346 (19.0) 443 (19.3)
Charlson score
0 3,945 (41.5) 3,007 (38.4) 712 (39.1) 937 (40.8)
1-3 3,831 (40.3) 3,222 (42.2) 783 (43.0) 931 (40.5)
> 3 1,734 (18.2) 1,598 (20.4) 324 (17.8) 428 (18.6)
Hospitalizations 2,350 (24,7) 1,961 (25.1) 448 (24.6) 623 (27.1)*
In long-term care 1,146 (12.1)* 659 (8.4) 156 (8.6) 303 (13.2)
History of any fractures 1,051 (11.1) 704 (9.0) 162 (8.9) 272 (11.8)
History of DXA 5,641 (59.3)* 4,154 (53.1) 883 (48.5) 1,328 (57.8)
Dual Eligible 2,807 (29.5) 2,624 (33.5) 650 (35.7) 779 (33.9)
Eligible for low income subsidy 3,011 (31.7) 2,877 (36.8) 690 (37.9) 841 (36.6)
Entered Medicare part D coverage gap 1,826 (19.2) 1,613 (20.6) 367 (20.2) 471 (20.5)
Proton pump inhibitors 2,430 (25.6) 2,070 (26.5) 517 (28.4) 709 (30.9)
Doctor visit type
Internal Medicine visits 6,220 (65.4) 5,085 (65.0) 1,170 (64.3) 1,564 (68.1)
Family Practice visits 4,446 (46.8) 3,654 (46.7) 781 (42.9) 1,107 (48.2)
Medical Oncology visits 940 (9.9) 721 (9.2) 159 (8.7) 222 (9.7)
Rheumatology/Endo visits 1,706 (17.9) 1,150 (14.7) 304 (16.7) 430 (18.7)*
Number of Physician Visits
0-5 2,978 (31.3) 2,305 (29.4) 571 (31.4) 579 (25.2)
6-10 2,516 (26.5) 2,018 (25.8) 462 (25.4) 578 (25.2)
11-15 1,665 (17.5) 1,379 (17.6) 307 (16.9) 438 (19.1)
> 15 2,351 (24.7) 2,125 (27.1) 479 (26.3) 701 (30.5)
Numbers in table are n (column percent) or mean (standard deviation).
*Standardized difference score between current column and continued original bisphosphonate use column is greater than 0.1.
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Table 2 Odds ratios (ORs) and 95% confidence intervals (CIs) for the association between baseline factors and
discontinuation of bisphosphonate therapy at 12 months of follow-up based on discontinuation definition I during the
period 2006–2009, cohort analyses
Discontinuation definition Ia
Patient baseline characteristics Adjustedb OR (95% CI)
Sex Male vs Female 1.1 (1.0-1.2)*
Race Black vs White 1.1 (0.9-1.2)
Asian vs White 0.9 (0.8-1.0)
Hispanic vs White 1.1 (1.0-1.3)*
Other vs White 1.0 (0.9-1.2)
Age 70-74 vs 65-69 1.0 (0.9-1.1)
75-79 vs 65-69 1.0 (0.9-1.1)
80-84 vs 65-69 1.0 (0.9-1.1)
85plus vs 65-69 1.0 (0.9-1.1)
Region Midwest vs Northeast 0.9 (0.8-1.0)
South vs Northeast 1.1 (1.0-1.2)*
West vs Northeast 1.0 (0.9-1.1)
Area income 45000 30000- vs < 30000 0.9 (0.8-1.0)
60000 45000- vs < 30000 0.9 (0.8-0.9)*
75000 60000- vs < 30000 0.9 (0.8-0.9)*
75000+ vs < 30000 0.8 (0.8-0.9)*
Charlson score 1-2 vs 0 1.0 (0.9-1.1)
> 2 vs 0 1.1 (1.0-1.2)*
Number of physician visits 6-10 vs 0-5 1.1 (1.0-1.2)
11-15 vs 0-5 1.1 (1.0-1.2)*
> 15 vs 0-5 1.3 (1.1-1.4)*
Hospitalization at baseline 1.0 (1.0-1.1)
Long-term care stay at baseline 0.6 (0.5-0.7)*
Fracture at baseline 0.9 (0.8-1.0)*
Dual-energy X-ray absorptiometry at baseline 0.8 (0.8-0.9)*
Internal medicine physician visit at baseline 1.0 (0.9-1.0)
Family practice physician visit at baseline 1.0 (0.9-1.1)
Oncologist visit at baseline 0.9 (0.8-1.0)*
Rheumatologist or endocrinologist visit at baseline 0.8 (0.7-0.9)*
Osteoporosis 0.8 (0.8-0.9)*
Proton pump inhibitors 0.8 (0.7-1.0)*
aDiscontinuation definition I: Totally discontinued all anti-osteoporosis drugs as of the end of follow up.
bAdjusted for all factors listed in the table, and urban/rural residency, entering Medicare part D coverage gap at baseline, glucocorticoid-related and fall-related
(predisposing to falls) conditions, diabetes, chronic kidney disease, depressive illness, acute myocardial infarction, other heart disease, metabolic bone disease,
cancer, anticonvulsants, antidepressants, antipsychotics, antihypertensives, lipid-lowering drugs, non-steroidal anti-inflammatory drugs, steroids, H2-receptor
blockers, hormone replacement therapy, thiazolidinediones, and aromatase inhibitors.
*p < =0.05.
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patients who stopped bisphosphonate therapy for at least
60 days, an estimated 30% restarted treatment within six
months [4]. Their results are higher than the percentage
restarting in our study, possibly because the prior ana-
lysis examined the therapeutic class of all bisphospho-
nates combined, while our analysis examined eachform of bisphosphonate separately. Brookhart et al. also
defined a gap as 60 days, whereas we used a gap length of
90 days. Another study, in a commercial health plan
population during the period of 2006–2008, reported sub-
stantial discontinuation, restarting, and switching among
new users of various anti-osteoporosis medications [29].
For example, 52-67% of new users of specific types of
Table 3 Odds ratios (ORs) and 95% confidence intervals (CIs) for the association between precipitating factors and
discontinueation of bisphosphonate therapy, case-crossover analysis
Factors potentially associated with discontinuationa Univariate analysis Multivariate analysis
OR (95% CI) Adjustedb OR (95% CI)
Dual-energy X-ray absorptiometry 2.0 (1.3-3.1) 2.3 (1.4-3.6)
Any hospitalization 2.2 (1.5-3.1) 1.7 (1.1-2.7)
Fracture 0.7 (0.2-1.9) 0.4 (0.1-1.3)
Cancer 1.2 (0.7-1.9) 1.0 (0.6-1.8)
Entering Medicare part D coverage gap 1.0 (0.8-1.3) 0.9 (0.7-1.3)
Adverse effects 1.6 (1.1-2.3) 1.0 (0.7-1.6)
Skilled nursing home 0.7 (0.2-2.1) 0.4 (0.1-1.4)
Rheumatologist or endocrinologist visit 1.1 (0.7-1.7) 0.8 (0.5-1.4)
Upper gastrointestinal disease 3.2 (1.4-7.3) 3.4 (1.5-7.7)
Eligible for low income subsidy 4.9 (0.8-28.7) 5.7 (1.0-32.4)
Number of ambulatory physician visits during each 30 day period
0 Ref (1.0) Ref (1.0)
1-4 1.2 (1.0-1.4) 1.2 (1.0-1.5)
> 4 2.4 (1.4-4.1) 2.5 (1.3-4.5)
Number of medications during each 30 day period
0-2 Ref (1.0) Ref (1.0)
3-5 0.8 (0.7-1.0) 0.5 (0.4-0.6)
> 5 0.5 (0.4-0.7) 0.3 (0.2-0.4)
Charlson score during each 30 day period
0 Ref (1.0) Ref (1.0)
1-2 1.3 (0.8-1.9) 1.4 (0.9-2.1)
> 2 1.7 (1.0-3.1) 2.5 (1.3-4.7)
Total Medicare cost during each 30-day period
$ 0-90 Ref (1.0) Ref (1.0)
$ 91-440 0.9 (0.7-1.1) 0.9 (0.7-1.1)
$ > 440 1.0 (0.8-1.3) 0.9 (0.8-1.3)
Out-of-pocket drug payments during each 30 day period
$ 0-19 Ref (1.0) Ref (1.0)
$ 20-84 1.6 (1.2-2.0) 1.6 (1.3-2.1)
$ > 84 5.4 (4.4-6.7) 6.6 (5.3-8.1)
aHazard period is defined as 30 days immediately before discontinuation. Control periods are defined as five 30-day periods immediately before the hazard period.
bAdjusted all the factors listed in the table.
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http://www.biomedcentral.com/1471-2474/15/112bisphosphonates discontinued their original medication
within 12 months, 13-22% restarted their original medi-
cation after a greater than 90-day treatment gap, and
0.4-9.6% switched to another drug. Therefore, examin-
ing patterns of restarting and switching in future osteopor-
osis studies may generate a more complete definition and
assessment of adherence, particularly in studies that include
time periods when a major new anti-osteoporosis medica-
tion, such as generic alendronate, has been introduced.
Regardless of length of follow-up or the definition of
discontinuation, the factors that we assessed at baseline
displayed generally weak associations or no relation withdiscontinuation. With area under the receiver operator
curve as low as 0.58-0.60 in both multivariable logistic
models, these results are consistent with those of prior
studies reporting that baseline characteristics, measured
only at treatment initiation, yielded a poor ability to dis-
criminate osteoporosis patients with high adherence ver-
sus low adherence [30].
Our case-crossover analysis was designed to identify fac-
tors emerging during follow-up that lead to discontinu-
ation among adherent bisphosphonate users. The results
indicated that events occurring during follow-up are likely
to be more important as predictors of adherence and
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apy initiation. Specifically, we identified six important
factors that were positively associated with discontinu-
ation – DXA, more than four ambulatory physician visits,
hospitalization, upper gastrointestinal disorders, higher
Charlson comorbidity index, and higher out-of-pocket
drug payments.
DXA is the gold standard for diagnosing osteoporosis,
and it may play a role in monitoring response to osteo-
porosis treatment [31]. Our finding that after one year of
high adherence, having a DXA was significantly associ-
ated with discontinuation, suggests that physicians and
patients may consider discontinuing osteoporosis medi-
cations if DXA test results indicate a bone mineral dens-
ity improvement treatment [32] or that patients may
discontinue the therapy due to a lack of improvement in
bone mineral density [33]. Unfortunately Medicare data
do not include DXA test results, which would be re-
quired to confirm this interpretation. Our observation
that having more than four ambulatory physician visits
was strongly associated with discontinuation contrasts
with another study that reported that physician visits
were related to patients’ reinitiating therapy [4]. The dis-
cordant results may reflect differences in study popula-
tions: our case-crossover analysis was limited to people
who had been adherent for at least one year and then
experienced discontinuation, whereas the latter study
was limited to new users. Also, it is possible that patients
with more diseases tend to see physicians more often
and stop taking drugs with fewer perceived beneficial ef-
fects [34,35].
Our study confirms results from other investigations
reporting that upper gastrointestinal conditions are sig-
nificantly associated with bisphosphonate discontinu-
ation [1,11]. Finally, our findings indicate that patients
who have more comorbid conditions, pay more out-of-
pocket for drugs, or stay in the hospital are much more
likely to discontinue drug therapy. These associations
are consistent with the phenomenon called the “sick
stopper”, wherein patients who are getting sicker and
spending more healthcare dollars maybe more likely to
discontinue treatments for non-symptomatic conditions,
such as osteoporosis [35].
A major strength of our study was its assessment of
factors possibly associated with discontinuation both
at baseline and, in the case-crossover analysis, during
follow-up. Other strengths include the study’s large size,
generalizability to the entire US traditional fee-for-service
Medicare population with Part D coverage, the use of
prescription claims to define exposures instead of self-
reported drug usage, and our sensitivity analyses. The
methodological aspects to our work should grow in im-
portance given increasing interest on drug holidays from
bisphosphonate exposure. We varied the definition ofdiscontinuation across a range of possible options and
examined factors associated with discontinuation, which
is expected to be useful for future analyses that examine
new reasons for patients to stop therapy such as a drug
holidays [15,16].
The main limitation was the study’s reliance on claims
data to assess utilization and possible reasons for discon-
tinuation. Claims data do not includes baseline or follow-
up bone mineral density measures, which could have
influenced the likelihood of adherence. Our case-crossover
analysis was limited to patients who had been adher-
ent to bisphosphonates for 12 months, whereas the
cohort analysis used new users, therefore, the charac-
teristics of subjects discontinuing included in the case-
crossover analysis were not comparable to those totally
discontinued in the cohort analysis. There also could
be misclassification of safety outcomes without well vali-
dated claims-based algorithms (e.g., osteonecrosis of the
jaw, atypical fracture, and upper gastrointestinal symp-
toms). The possibility that some patients may have filled
their anti-osteoporosis prescriptions without submitting
a claim to Medicare is another potential limitation.
However, we recently reported that this may occur for a
maximum of 15% of generic prescriptions, using alendro-
nate as an example, available through low-cost pharmacy
programs [36].
Finally, our analyses included patients who had pri-
mary adherence (i.e., they filled a prescription for a bis-
phosphonate), but not patients with primary non-adherence
(i.e., had anti-osteoporosis prescriptions but never have it
filled or administrated), and our case-crossover analysis
was further restricted to patients who were adherent for
12 months after initiation of therapy. Thus, the results
may not be generalizable to all Medicare patients pre-
scribed and taking bisphosphonate drugs.
Conclusions
Generic alendronate and IV zoledronic use among Medi-
care beneficiaries increased substantially during 2007–
2009. Among new bisphosphonate users, switching among
bisphosphonates, switching out of the bisphosphonate
therapeutic class, and having treatment gaps were com-
mon. Factors measured at therapy initiation were at most
weakly associated with discontinuation, regardless of vary-
ing the definition of discontinuation and the length of
follow-up. In contrast, several factors measured during
follow-up appeared to precipitate discontinuation within
12 months of initiating bisphosphonate therapy in-
cluding DXA, more than six ambulatory physician visits,
hospitalization, upper gastrointestinal disorders, higher
Charlson comorbidity score, and higher out-of-pocket
drug payments. Further studies are needed to characterize
medication discontinuation more carefully with consider-
ation of time-varying factors.
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